Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Listeria meningoencephalitis and anti-GQ1b antibody syndrome.
Vergori A, Masi G, Donati D, Ginanneschi F, Annunziata P, Cerase A, Mencarelli M, Rossetti B, De Luca A, Zanelli G. Vergori A, et al. Infection. 2016 Aug;44(4):543-6. doi: 10.1007/s15010-015-0862-y. Epub 2016 Jan 29. Infection. 2016. PMID: 26825308
HIV and Co-Infections: Updates and Insights.
Di Gennaro F, Vergori A, Bavaro DF. Di Gennaro F, et al. Among authors: vergori a. Viruses. 2023 Apr 29;15(5):1097. doi: 10.3390/v15051097. Viruses. 2023. PMID: 37243183 Free PMC article.
Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the ICONA network.
Giacomelli A, Gagliardini R, Tavelli A, De Benedittis S, Mazzotta V, Rizzardini G, Mondi A, Augello M, Antinori S, Vergori A, Gori A, Menozzi M, Taramasso L, Fusco FM, De Vito A, Mancarella G, Marchetti G, D'Arminio Monforte A, Antinori A, Cozzi-Lepri A; COVID-19 ICONA study group. Giacomelli A, et al. Among authors: vergori a. Int J Infect Dis. 2023 Nov;136:127-135. doi: 10.1016/j.ijid.2023.09.015. Epub 2023 Sep 22. Int J Infect Dis. 2023. PMID: 37741311 Free article.
Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV.
Vergori A, Matusali G, Lepri AC, Cimini E, Fusto M, Colavita F, Gagliardini R, Notari S, Mazzotta V, Mariotti D, Cicalini S, Girardi E, Vaia F, Maggi F, Antinori A; HIV-VAC Study group. Vergori A, et al. Int J Infect Dis. 2023 Sep;134:195-199. doi: 10.1016/j.ijid.2023.06.010. Epub 2023 Jun 19. Int J Infect Dis. 2023. PMID: 37343783 Free PMC article.
Investigating coping and stigma in people living with HIV through narrative medicine in the Italian multicentre non-interventional study DIAMANTE.
Antinori A, Vergori A, Ripamonti D, Valenti D, Esposito V, Carleo MA, Rusconi S, Cascio A, Manzillo E, Andreoni M, Orofino G, Cappuccio A, Reale L, Marini MG, Mancusi D, Termini R, Uglietti A, Portaro M. Antinori A, et al. Among authors: vergori a. Sci Rep. 2023 Oct 17;13(1):17624. doi: 10.1038/s41598-023-44768-2. Sci Rep. 2023. PMID: 37848464 Free PMC article.
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals.
Armenia D, Gagliardini R, Alteri C, Svicher V, Cento V, Borghi V, Vergori A, Cicalini S, Forbici F, Fabeni L, Bertoli A, Brugneti M, Gennari W, Malagnino V, Andreoni M, Mussini C, Antinori A, Perno CF, Santoro MM, Ceccherini-Silberstein F. Armenia D, et al. Among authors: vergori a. J Clin Virol. 2023 Nov;168:105551. doi: 10.1016/j.jcv.2023.105551. Epub 2023 Jul 23. J Clin Virol. 2023. PMID: 37573167 Free article.
Telemedicine During COVID-19 Pandemic: Lesson Learned from the Lazio Region Infectious Diseases and Emergency Department Network.
Maffongelli G, Bevilacqua N, Vita S, Bartoli TA, Corpolongo A, Benvenuto D, Chiriaco T, Spiga G, Ribaldi S, Zirretta V, Ippolito G, Lauria FN, Vaia F, Nicastri E; COVID Group of the Lazio Region; Bed Manager Group at INMI Spallanzani. Maffongelli G, et al. J Med Syst. 2022 Dec 7;46(12):105. doi: 10.1007/s10916-022-01887-z. J Med Syst. 2022. PMID: 36473993 Free PMC article.
Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study).
Mastrorosa I, Gagliardini R, Segala FV, Mondi A, Lorenzini P, Cerva C, Taddei E, Bai F, Vergori A, Marcantonio N, Pinnetti C, Cicalini S, Murri R, Mazzotta V, Camici M, Mosti S, Bini T, Maffongelli G, Beccacece A, Milozzi E, Iannetta M, Lamonica S, Fusto M, Plazzi MM, Ottou S, Lichtner M, Fantoni M, Andreoni M, Sarmati L, Cauda R, Girardi E, Nicastri E, D'Arminio Monforte A, Palmieri F, Cingolani A, Vaia F, Antinori A; ESCAPE study group. Mastrorosa I, et al. Among authors: vergori a. EClinicalMedicine. 2023 Mar 10;57:101895. doi: 10.1016/j.eclinm.2023.101895. eCollection 2023 Mar. EClinicalMedicine. 2023. PMID: 36936403 Free PMC article.
Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation.
Ciccosanti F, Antonioli M, Sacchi A, Notari S, Farina A, Beccacece A, Fusto M, Vergori A, D'Offizi G, Taglietti F, Antinori A, Nicastri E, Marchioni L, Palmieri F, Ippolito G, Piacentini M, Agrati C, Fimia GM. Ciccosanti F, et al. Among authors: vergori a. Clin Proteomics. 2022 Nov 8;19(1):38. doi: 10.1186/s12014-022-09377-7. Clin Proteomics. 2022. PMID: 36348270 Free PMC article.
125 results